Literature DB >> 2504043

The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.

C J Lockwood1, R Romero, R F Feinberg, L P Clyne, B Coster, J C Hobbins.   

Abstract

Circulating antibodies to negatively-charged phospholipids have been implicated in the genesis of adverse pregnancy outcomes. However, it has yet to be established that these antibodies are causative or that they are invariably associated with untoward perinatal outcomes. To address this issue, the prevalence of lupus anticoagulant and anticardiolipin antibodies was recorded in a low-risk obstetric population, and the outcome of untreated pregnancies were evaluated. Two of 737 patients (0.27%) had lupus anticoagulant documented by a prolonged activated partial thromboplastin time that did not correct this mixing studies. In comparison, greatly elevated concentrations of immunoglobulin M-anticardiolipin antibodies or immunoglobulin G-anticardiolipin antibodies were identified in 16/737 (2.2%) patients by means of an enzyme-linked immunosorbent assay. Spontaneous abortions occurred in both lupus anticoagulant-positive patients, suggesting that the activated partial thromboplastin time used was a relatively insensitive but specific marker for antiphospholipid antibody-associated adverse pregnancy outcomes. In contrast, although 12 of 16 anticardiolipin antibodies-positive pregnancies were complicated by perinatal loss, preterm delivery, or fetal growth retardation, four patients had uncomplicated pregnancies. Moreover, the distribution of anticardiolipin antibodies concentrations in these four patients was not clustered among the lowest anticardiolipin antibodies values, and anticardiolipin antibodies concentrations correlated weakly with adverse outcomes. These findings suggest that antiphospholipid antibodies are related to adverse pregnancy outcomes in a complex fashion and that therapy is not always required for acceptable outcomes in patients without other risk factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504043     DOI: 10.1016/0002-9378(89)90522-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  27 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Acute myocardial infarction due to antiphospholipid antibody syndrome in a young pregnant woman.

Authors:  Huseyin Altug Cakmak; Serkan Aslan; Eser Durmaz; Bilgehan Karadag; Rasim Enar
Journal:  J Cardiol Cases       Date:  2011-05-31

3.  Incidence of anticardiolipin antibodies and lupus anticoagulant factor among women experiencing unexplained recurrent abortion and intrauterine fetal death.

Authors:  Noura Al Jameil; Poonam Tyagi; Amal Al Shenefy
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

5.  Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden.

Authors:  Tracy Manuck; D Ware Branch; Yinglei Lai; Baha Sibai; Catherine Y Spong; George Wendel; Katharine Wenstrom; Philip Samuels; Steve N Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner
Journal:  J Reprod Immunol       Date:  2010-05-02       Impact factor: 4.054

6.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

Review 7.  Anticoagulant therapy and pregnancy.

Authors:  Aiko Makino; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2008-02-01

Review 8.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

Review 9.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 10.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.